The 2026 peptide regulatory landscape: a plain-English map
The short version: peptide regulation in 2026 is in motion. Some compounds are accessible, some are not, and the line between them is being redrawn by the FDA, the courts, and the PCAC advisory committee.
TL;DR
- Category 1 peptides may be prepared by 503A compounding pharmacies; Category 2 peptides may not.
- The February 2026 HHS announcement signaled intent to return several peptides to Category 1.
- The PCAC July 2026 meeting and ongoing litigation will shape the rest of 2026.
What the landscape is
The U.S. peptide regulatory landscape (in plain English: the set of FDA rules, court decisions, and advisory committee recommendations that determine which peptides can be prescribed and compounded) is built on three layers. The first layer is FDA approval — only a small number of peptides are FDA-approved as finished products (semaglutide, tirzepatide, sermorelin acetate when it was branded, bremelanotide as Vyleesi, tesamorelin). The second layer is compounding — state-licensed 503A pharmacies may compound certain peptides for individual patients. The third layer is enforcement — FDA warning letters, Federal Register notices, and court rulings shape what is happening on the ground.
How the system works
Think of the system as a three-light traffic signal. Green light: Category 1 peptides may be compounded by 503A pharmacies (sermorelin, CJC-1295, ipamorelin, GHK-Cu, PT-141, oxytocin, MK-677 in many states, IGF-1 LR3 in many states). Red light: Category 2 peptides may not be compounded by 503A pharmacies (BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, melanotan-2, Selank, Semax). Yellow light: peptides under active review or transition. The FDA's compounding bulk-drug-substance list (FDA, 2026) is the official source.
Who is affected
Patients, prescribing clinicians, and 503A pharmacies are all directly affected. About 1 in 6 longevity-focused medical practices reported having to change a patient's protocol after the 2023 Category 2 reclassification. The downstream effect — gray-market sourcing, inconsistent quality, prescriber confusion — is one reason ongoing regulatory clarity matters.
What changed in 2026
The February 2026 HHS announcement signaled intent to return several peptides to Category 1, pending formal FDA Federal Register notice (Federal Register portal). For some peptides, that notice has issued. For others, it has not. The Novo Nordisk v. Hims & Hers (Feb 2026) litigation continues to shape compounded GLP-1 access. The PCAC is scheduled to meet in July 2026 with peptides on the agenda.
What to know before considering it
The legal status of any specific peptide should be confirmed at the time of prescribing — not assumed from a prior conversation. Compounded peptides are not FDA-approved. A licensed clinician evaluation is required.
The Halftime POV
The 2026 landscape is unsettled, and that is the most accurate sentence to write about it. Mapping the system honestly — not selling certainty that does not exist — is the only responsible posture.
Related reading:
- Category 1 vs Category 2 peptides: the access framework
- The February 2026 HHS announcement on peptide reclassification
- What the July 2026 PCAC meeting could change
FAQ
Q: Are compounded peptides legal in 2026? A: Some are; some are not. Peptides classified by the FDA as Category 1 may be compounded by 503A pharmacies. Category 2 peptides may not. The list shifts as the FDA reviews petitions and PCAC issues recommendations.
Q: What did the February 2026 HHS announcement do? A: It signaled an intent to return several peptides from Category 2 to Category 1 access, but a formal change requires an FDA Federal Register notice. As of mid-2026, that notice is still pending for some peptides and has been issued for others.
Q: Is the regulatory landscape still changing? A: Yes. The PCAC (Pharmacy Compounding Advisory Committee) is scheduled to meet in July 2026 with peptides on the agenda. New Federal Register notices, court decisions, and warning letters continue to shape the picture month by month.
Disclaimer
As of 2026-05-07, several peptides discussed in this article — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, melanotan-2, Selank, and Semax — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- Federal Register — Food and Drug Administration agency portal
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Are compounded peptides legal in 2026?
Some are; some are not. Peptides classified by the FDA as Category 1 may be compounded by 503A pharmacies. Category 2 peptides may not. The list shifts as the FDA reviews petitions and PCAC issues recommendations.
What did the February 2026 HHS announcement do?
It signaled an intent to return several peptides from Category 2 to Category 1 access, but a formal change requires an FDA Federal Register notice. As of mid-2026, that notice is still pending for some peptides and has been issued for others.
Is the regulatory landscape still changing?
Yes. The PCAC (Pharmacy Compounding Advisory Committee) is scheduled to meet in July 2026 with peptides on the agenda. New Federal Register notices, court decisions, and warning letters continue to shape the picture month by month.
